On January 24, 2018 Novartis CEO Joe Jimenez reported fourth quarter and full year 2017 results (Press release, Novartis, JAN 23, 2018, View Source [SID1234523565]). In his remarks Jimenez said: "It was a landmark year for innovation resulting in a rich late-stage pipeline. With several key launches on the horizon and our new operating model in place, Novartis is poised for sustainable growth."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vas Narasimhan, designated CEO from February 1, commented: "I want to thank Joe and the Board for their leadership and guidance as I transition to my new role. I feel privileged to lead Novartis at this exciting time."